RevelAi Health and Zimmer Biomet agree to advance value-based care and health equity through AI-powered technology 

RevelAi Health and Zimmer Biomet agree to advance value-based care and health equity through AI-powered technology 

Health and Zimmer Biomet Holdings, a global medical technology leader, has announced a multi-year co-marketing agreement to commercialise GenAI-powered engagement solutions that advance value-based orthopaedic care and health equity. During the multi-year agreement, Zimmer Biomet will commercialise RevelAi Health’s patient care-management platform, care team dashboard for providers and any future products or services. 

“Leveraging generative AI to streamline clinical care workflows while addressing socio-demographic disparities is a unique opportunity to drive equitable value-based outcomes,” said Christian Péan MD, MS, CEO of RevelAi Health and an orthopedic trauma surgeon at Duke University School of Medicine. “Our AI-enabled asynchronous care model delivers personalised, timely, and effective patient care while reducing clinician burnout.  Our collaboration with Zimmer Biomet is a significant step towards ensuring that every patient receives the care they deserve.” 

RevelAi health is a software as a service (SAAS) health technology company that specialises in cutting-edge GenAI population health solutions.  RevelAi Health’s clinician-validated large language model helps healthcare providers transition seamlessly to value-based care, meeting essential CMS (Centers for Medicare and Medicaid Services) requirements, including Patient Reported Outcome measures and Social Drivers of Health (SDOH) Screening. 

Browse our latest issue

Intelligent Health.tech

View Magazine Archive